Brand Name | Status | Last Update |
---|---|---|
mylotarg | Biologic Licensing Application | 2025-04-01 |
Code | Description |
---|---|
J9203 | Injection, gemtuzumab ozogamicin, 0.1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | — | 1 | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | — | — | 1 | — | — | 1 |
Bone marrow transplantation | D016026 | — | — | — | — | 1 | — | — | 1 |
Acute disease | D000208 | — | — | — | — | 1 | — | — | 1 |
Drug common name | Gemtuzumab |
INN | gemtuzumab |
Description | Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108342 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00056 |
UNII ID | 8GZG754X6M (ChemIDplus, GSRS) |